Bharat Parenterals Limited

BSE: 541096
Bharat Parenterals Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials and compliance.
CIN L24231GJ1992PLC018237 Incorporated 03 September 1992 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - BSE: 541096 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹345.43 Cr
▲ 1.48% YoY
Computed EBITDA · FY 2026
₹25.36 Cr
▲ 73.71% YoY
Net profit · FY 2026
-₹27.31 Cr
▲ 37.49% YoY
Authorised capital
₹8 Cr
Registered with MCA
Paid-up capital
₹6.89 Cr
Issued & subscribed
Open charges
₹145.09 Cr
Satisfied ₹34.12 Cr
Company age
34 yrs
Est. 1992
Employees · EPFO
396
Latest available

About Bharat Parenterals Limited

Data last updated: 14 July 2026

Bharat Parenterals Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 03 September 1992, the company has been in operation for over 34 years.

Registered with ROC Ahmedabad under CIN L24231GJ1992PLC018237. Listed on BSE: 541096.

Capital: an authorised share capital of ₹8 Cr and a paid-up capital of ₹6.89 Cr. It is led by directors including Hemang Jayendrabhai Shah and Shaileshkumar Gabhawala.

Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520.

As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹345.43 Cr, a growth of 1.48% compared to the previous year. The net worth stands at ₹311.58 Cr (down 8.09% YoY). Total assets are valued at ₹613.3 Cr (down 5.43% YoY).

The company has a workforce of approximately 396 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Bharat Parenterals. As per MCA filings, the company has open charges of ₹145.09 Cr and satisfied charges of ₹34.12 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bplindia.in.

Company Details of Bharat Parenterals Limited
CIN L24231GJ1992PLC018237
Registration Number 018237
Incorporation Date 03 September 1992
ROC Ahmedabad
Listing Status Listed (BSE: 541096)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Bharatkumar Rameshchandra Desai Managing Director Hemang Jayendrabhai Shah Director Shaileshkumar Gabhawala Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    bplindia.in
  • Social Media
  • Registered Address
    Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520
  • Industry
    Pharma, Drug Formulation & Development
Company report
Bharat Parenterals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Bharat Parenterals Limited report

Financials, compliance, directors, charges, ownership and filings for Bharat Parenterals Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Bharat Parenterals Limited

Bharat Parenterals Limited has one previous CIN (Corporate Identification Number): U24231GJ1992PLC018237. The current CIN is L24231GJ1992PLC018237, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24231GJ1992PLC018237 Current
U24231GJ1992PLC018237 Previous

Associated Brands with Bharat Parenterals Limited

Bharat Parenterals Limited operates one associated brand: Bharat Parenterals. These brands represent Bharat Parenterals Limited's diversified market presence and brand portfolio.

Brand Description Website
Bharat Parenterals
Pharmaceutical formulations are manufactured for domestic and international markets. bplindia.in

Competitors & Alternatives of Bharat Parenterals Limited

Brands and companies operating in the same space as Bharat Parenterals Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Windlas Windlas Biopharma regulatory affairs, quality control, and strategy services are provided. Gurugram, India, India 2001
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
MedPharm MedPharm Topical and inhaled drug delivery formulations are developed and manufactured. Guildford, United Kingdom, United Kingdom 1998

Business Activity of Bharat Parenterals Limited

Bharat Parenterals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Bharat Parenterals Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Bharat Parenterals Limited

Bharat Parenterals Limited is audited by M/s Shah Mehta & Bakshi (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s Shah Mehta & Bakshi (ICAI peer reviewed, certificate valid till 2028-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Bharat Parenterals Limited

Bharat Parenterals Limited is currently managed by 6 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Hemang Jayendrabhai Shah Director 08 Jul 2010 16 Years 1 Months Current
Shaileshkumar Gabhawala
Also directs: S.L. Infrabuildcon Private Limited
Director 03 Aug 2017 9 Years 0 Months Current
Mukeshbhai Jivrajbhai Patel
Also directs: Agroxa Bio Innovations Llp, Innoxel Lifesciences Private Limited, Agriland Biotech Limited
Director 26 Sep 2020 5 Years 10 Months Current
Bharatkumar Rameshchandra Desai
Also directs: Innoxel Lifesciences Private Limited, Pharmaceuticals Export Promotion Council Of India, Varenyam Biolifesciences Private Limited
Managing Director 03 Sep 1992 33 Years 11 Months Current
Zankhana Bimalkumar Sheth
Also directs: Innoxel Lifesciences Private Limited
Director 14 Aug 2018 8 Years 0 Months Current
Alkesh Jayantilal Shah Director 28 Jul 2025 1 Years 0 Months Current
View all directors

Financials of Bharat Parenterals Limited FY 2026 filings available

Bharat Parenterals Limited reported revenue of ₹345.43 Cr (up 1.48% YoY) for FY 2026.

Revenue · FY 2026
₹345.43 Cr ▲ 1.48%
Profit · FY 2026
-₹27.31 Cr ▲ 37.49%
Computed EBITDA · FY 2026
₹25.36 Cr ▲ 73.71%
Revenue₹ Cr · Consolidated0200400FY 2019: ₹220 Cr220FY 2019FY 2020: ₹228 Cr · +3.9% YoY228+3.9%FY 2020FY 2021: ₹205 Cr · -10.3% YoY205-10.3%FY 2021FY 2022: ₹212 Cr · +3.6% YoY212+3.6%FY 2022FY 2023: ₹218 Cr · +2.8% YoY218+2.8%FY 2023FY 2024: ₹257 Cr · +18.1% YoY257+18.1%FY 2024FY 2025: ₹340 Cr · +32.3% YoY340+32.3%FY 2025FY 2026: ₹345 Cr · +1.5% YoY345+1.5%FY 2026
Net Profit₹ Cr · Consolidated-60-40-2002040FY 2019: ₹21 Cr21.2FY 2019FY 2020: ₹24 Cr · +13.7% YoY24.2+13.7%FY 2020FY 2021: ₹20 Cr · -15.9% YoY20.3-15.9%FY 2021FY 2022: ₹21 Cr · +2.5% YoY20.8+2.5%FY 2022FY 2023: ₹16 Cr · -24.5% YoY15.7-24.5%FY 2023FY 2024: ₹11 Cr · -33.1% YoY10.5-33.1%FY 2024FY 2025: ₹44 Cr (loss) · -515.2% YoY-43.7FY 2025FY 2026: ₹27 Cr (loss) · +37.5% YoY-27.3FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100150Q1'25: ₹93 Cr92.5Q1'25Q2'25: ₹72 Cr71.6Q2'25Q3'25: ₹72 Cr72.3Q3'25Q4'25: ₹104 Cr104Q4'25Q1'26: ₹116 Cr · +25.4% YoY116+25.4%Q1'26Q2'26: ₹65 Cr · -9.8% YoY64.6-9.8%Q2'26Q3'26: ₹65 Cr · -9.8% YoY65.2-9.8%Q3'26Q4'26: ₹100 Cr · -4.2% YoY99.6-4.2%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹345.43 Cr ₹340.38 Cr ₹257.36 Cr ₹217.98 Cr ₹212.01 Cr ₹204.64 Cr ₹228.18 Cr ₹219.54 Cr
Other Income ₹9.54 Cr ₹11.9 Cr ₹8.59 Cr ₹11.74 Cr ₹7.78 Cr ₹8.68 Cr ₹11.48 Cr ₹12.7 Cr
Total Income ₹354.98 Cr ₹352.28 Cr ₹265.95 Cr ₹229.72 Cr ₹219.79 Cr ₹213.32 Cr ₹239.66 Cr ₹232.25 Cr
Cost of Materials Consumed ₹169.26 Cr ₹178.17 Cr ₹173.16 Cr ₹146.07 Cr ₹132.72 Cr ₹127.13 Cr ₹130.73 Cr ₹95.97 Cr
Purchases of Stock-in-Trade ₹17.41 Cr ₹7.76 Cr ₹38 Lakh ₹1.16 Cr ₹1.66 Cr ₹5.33 Cr ₹21.15 Cr ₹46.12 Cr
Changes in Inventories ₹4.73 Cr -₹45 Lakh -₹15.18 Cr -₹9.75 Cr ₹1.68 Cr ₹1.8 Cr -₹2.97 Cr -₹1.61 Cr
Employee Benefit Expense ₹67.28 Cr ₹49.66 Cr ₹22.78 Cr ₹18 Cr ₹15.37 Cr ₹14.75 Cr ₹15.58 Cr ₹15.37 Cr
Finance Costs ₹12.53 Cr ₹13.23 Cr ₹3.22 Cr ₹2.19 Cr ₹89 Lakh ₹77 Lakh ₹86 Lakh ₹86.99 Lakh
Depreciation & Amortisation ₹34.25 Cr ₹35.32 Cr ₹9.02 Cr ₹5.88 Cr ₹6.66 Cr ₹6.03 Cr ₹5.88 Cr ₹6.13 Cr
Other Expenses ₹70.94 Cr ₹102.54 Cr ₹53.85 Cr ₹42.62 Cr ₹32.93 Cr ₹30.39 Cr ₹35.62 Cr ₹34.81 Cr
Total Expenses ₹376.4 Cr ₹386.23 Cr ₹247.23 Cr ₹206.17 Cr ₹191.91 Cr ₹186.2 Cr ₹206.85 Cr ₹197.65 Cr
Profit Before Exceptional Items & Tax -₹21.42 Cr -₹33.95 Cr ₹18.72 Cr ₹23.55 Cr ₹27.88 Cr ₹27.12 Cr ₹32.81 Cr ₹34.59 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹21.42 Cr -₹33.95 Cr ₹18.72 Cr ₹23.55 Cr ₹27.88 Cr ₹27.12 Cr ₹32.81 Cr ₹34.59 Cr
Total Tax Expense ₹5.88 Cr ₹9.22 Cr ₹8.23 Cr ₹7.83 Cr ₹7.07 Cr ₹6.81 Cr ₹8.65 Cr ₹13.35 Cr
Net Profit -₹27.31 Cr -₹43.68 Cr ₹10.52 Cr ₹15.72 Cr ₹20.81 Cr ₹20.31 Cr ₹24.16 Cr ₹21.25 Cr
  attributable to Owners -₹8.19 Cr ₹0 - ₹16.44 Cr ₹21.05 Cr ₹20.39 Cr ₹0 ₹0
  attributable to NCI -₹19.12 Cr ₹0 - -₹68 Lakh -₹24 Lakh -₹7 Lakh ₹0 ₹0
Other Comprehensive Income ₹57.72 Lakh ₹20 Lakh -₹20 Lakh ₹4 Lakh -₹23 Lakh ₹16 Lakh ₹4 Lakh -₹8.8 Lakh
Total Comprehensive Income -₹26.73 Cr -₹43.48 Cr ₹10.32 Cr ₹15.76 Cr ₹20.58 Cr ₹20.47 Cr ₹24.2 Cr ₹21.16 Cr
EBITDA (computed) ₹25.36 Cr ₹14.6 Cr ₹30.96 Cr ₹31.62 Cr ₹35.43 Cr ₹33.92 Cr ₹39.55 Cr ₹41.59 Cr
Basic EPS ₹-39.62 ₹-66.64 ₹8.65 ₹28.40 ₹36.67 ₹35.59 ₹42.14 ₹37.08
Diluted EPS ₹-39.62 ₹-66.64 ₹0.00 ₹28.40 ₹36.67 ₹35.59 ₹42.14 ₹37.08
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹613.3 Cr ₹648.53 Cr ₹503.81 Cr ₹350.34 Cr ₹226.06 Cr ₹198.65 Cr ₹187.5 Cr ₹158.93 Cr
Non-current Assets ₹300.26 Cr ₹292.5 Cr ₹243.9 Cr ₹166.06 Cr ₹82.32 Cr ₹50.62 Cr ₹55.88 Cr ₹40.91 Cr
Current Assets ₹313.04 Cr ₹356.03 Cr ₹259.91 Cr ₹184.28 Cr ₹143.74 Cr ₹148.03 Cr ₹131.62 Cr ₹118.02 Cr
Property, Plant & Equipment ₹201.6 Cr ₹198.88 Cr ₹209.48 Cr ₹41.19 Cr ₹39.75 Cr ₹43.36 Cr ₹31.75 Cr ₹33.98 Cr
Inventories ₹84.72 Cr ₹71.95 Cr ₹61.47 Cr ₹37.84 Cr ₹20.76 Cr ₹22.43 Cr ₹28.82 Cr ₹22.52 Cr
Trade Receivables ₹150.65 Cr ₹171.74 Cr ₹141.42 Cr ₹112.41 Cr ₹73.4 Cr ₹67.83 Cr ₹79.35 Cr ₹63.87 Cr
Cash & Equivalents ₹1.48 Cr ₹56 Lakh ₹8.71 Cr ₹7.85 Cr ₹3.4 Cr ₹1.68 Cr ₹10.1 Cr ₹11.07 Cr
Equity (Net Worth) ₹311.58 Cr ₹339 Cr ₹238.18 Cr ₹217.89 Cr ₹170.14 Cr ₹143.82 Cr ₹118.19 Cr ₹94.01 Cr
Equity Share Capital ₹6.89 Cr ₹6.89 Cr ₹5.82 Cr ₹5.77 Cr ₹5.77 Cr ₹5.73 Cr ₹5.73 Cr ₹5.73 Cr
Borrowings (Non-current) ₹121.79 Cr ₹75.87 Cr ₹0 ₹10.92 Cr ₹12.49 Cr ₹8.59 Cr ₹71 Lakh ₹96.5 Lakh
Borrowings (Current) ₹24.32 Cr ₹104.33 Cr ₹84.41 Cr ₹38.82 Cr ₹5.26 Cr ₹1.19 Cr ₹0 ₹1.95 Cr
Total Debt (computed) ₹146.11 Cr ₹180.2 Cr ₹84.41 Cr ₹49.74 Cr ₹17.75 Cr ₹9.78 Cr ₹71 Lakh ₹2.92 Cr
Current Liabilities ₹157.39 Cr ₹219.3 Cr ₹190.37 Cr ₹119.8 Cr ₹41.53 Cr ₹43.63 Cr ₹65.89 Cr ₹60.51 Cr
Total Liabilities ₹301.72 Cr ₹309.53 Cr ₹265.63 Cr ₹132.45 Cr ₹55.92 Cr ₹54.83 Cr ₹69.31 Cr ₹64.92 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹38.36 Cr -₹14.39 Cr -₹4.71 Cr ₹21.66 Cr -₹1.07 Cr
Investing Cash Flow ₹9.32 Cr -₹137.12 Cr -₹104.78 Cr -₹77.82 Cr -₹6.63 Cr
Financing Cash Flow -₹47.05 Cr ₹156.09 Cr ₹110.43 Cr ₹60.6 Cr ₹9.42 Cr
Capital Expenditure ₹39.93 Cr ₹29.08 Cr ₹104.3 Cr ₹91.6 Cr ₹38.95 Cr
Free Cash Flow (computed) -₹1.57 Cr -₹43.47 Cr -₹109.01 Cr -₹69.94 Cr -₹40.02 Cr
Dividends Paid ₹68.75 Lakh ₹58 Lakh ₹43 Lakh ₹0 ₹0
Net Change in Cash ₹63.61 Lakh ₹4.46 Cr ₹94 Lakh ₹4.44 Cr ₹1.72 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹99.62 Cr ₹65.19 Cr ₹64.62 Cr ₹116 Cr ₹103.98 Cr ₹72.26 Cr ₹71.63 Cr ₹92.51 Cr
Other Income ₹3.63 Cr ₹1.33 Cr ₹3.53 Cr ₹1.06 Cr ₹2.2 Cr ₹2.95 Cr ₹4.21 Cr ₹2.54 Cr
Total Income ₹103.25 Cr ₹66.52 Cr ₹68.15 Cr ₹117.06 Cr ₹106.18 Cr ₹75.21 Cr ₹75.84 Cr ₹95.05 Cr
Cost of Materials Consumed ₹51.35 Cr ₹26.11 Cr ₹31.41 Cr ₹54.83 Cr ₹51.18 Cr ₹45.25 Cr ₹26.94 Cr ₹54.8 Cr
Purchases of Stock-in-Trade ₹5.8 Cr ₹3.66 Cr ₹4.73 Cr ₹3.21 Cr ₹6.64 Cr ₹48 Lakh ₹0 ₹64 Lakh
Changes in Inventories ₹60.36 Lakh ₹2.53 Cr -₹9.22 Cr ₹10.81 Cr -₹4.28 Cr -₹10.06 Cr ₹14.76 Cr -₹87 Lakh
Employee Benefit Expense ₹18.46 Cr ₹17.03 Cr ₹16.49 Cr ₹15.3 Cr ₹18.14 Cr ₹10.98 Cr ₹10.62 Cr ₹9.92 Cr
Finance Costs ₹2.85 Cr ₹2.9 Cr ₹3.11 Cr ₹3.69 Cr ₹4.22 Cr ₹3.33 Cr ₹2.91 Cr ₹2.77 Cr
Depreciation & Amortisation ₹8.63 Cr ₹8.46 Cr ₹8.56 Cr ₹8.6 Cr ₹8.52 Cr ₹8.76 Cr ₹9.01 Cr ₹9.03 Cr
Other Expenses ₹23.94 Cr ₹14.11 Cr ₹20.39 Cr ₹18.08 Cr ₹30.06 Cr ₹21.97 Cr ₹26.98 Cr ₹23.53 Cr
Total Expenses ₹111.62 Cr ₹74.8 Cr ₹75.47 Cr ₹114.52 Cr ₹114.48 Cr ₹80.71 Cr ₹91.22 Cr ₹99.82 Cr
Profit Before Exceptional Items & Tax -₹8.37 Cr -₹8.28 Cr -₹7.32 Cr ₹2.54 Cr -₹8.3 Cr -₹5.5 Cr -₹15.38 Cr -₹4.77 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹8.37 Cr -₹8.28 Cr -₹7.32 Cr ₹2.54 Cr -₹8.3 Cr -₹5.5 Cr -₹15.38 Cr -₹4.77 Cr
Total Tax Expense -₹21.19 Lakh ₹1.39 Cr ₹1.29 Cr ₹3.41 Cr ₹96 Lakh ₹2.37 Cr ₹2.14 Cr ₹4.08 Cr
Net Profit -₹8.16 Cr -₹9.67 Cr -₹8.61 Cr -₹87 Lakh -₹9.44 Cr -₹7.87 Cr -₹17.52 Cr -₹8.85 Cr
  attributable to Owners -₹4.8 Cr -₹4.39 Cr -₹7.24 Cr ₹0 ₹0 -₹1.68 Cr -₹7.56 Cr -
  attributable to NCI -₹3.36 Cr -₹5.28 Cr -₹1.37 Cr ₹0 ₹0 -₹6.21 Cr -₹10.01 Cr -
Other Comprehensive Income ₹21.41 Lakh ₹33.42 Lakh ₹6 Lakh -₹4 Lakh ₹35 Lakh -₹5 Lakh -₹5 Lakh -₹5 Lakh
Total Comprehensive Income -₹7.95 Cr -₹9.34 Cr -₹8.55 Cr -₹91 Lakh -₹9.09 Cr -₹7.92 Cr -₹17.57 Cr -₹8.9 Cr
EBITDA (computed) ₹3.1 Cr ₹3.07 Cr ₹4.35 Cr ₹14.83 Cr ₹4.44 Cr ₹6.59 Cr -₹3.46 Cr ₹7.03 Cr
Basic EPS ₹-11.84 ₹-14.03 ₹-14.00 ₹-1.27 ₹-14.40 ₹-10.00 ₹-27.00 ₹-14.71
Diluted EPS ₹-11.84 ₹-14.03 ₹-14.00 ₹-1.27 ₹-14.40 ₹-10.00 ₹-27.00 ₹0.00
Latest 8 quarters shown.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹234.01 Cr ₹304.13 Cr ₹254.16 Cr ₹217.98 Cr ₹212.01 Cr ₹203.67 Cr ₹226.33 Cr ₹219.69 Cr
Other Income ₹12.55 Cr ₹14.56 Cr ₹11.96 Cr ₹18.84 Cr ₹7.78 Cr ₹8.67 Cr ₹11.48 Cr ₹12.7 Cr
Total Income ₹246.57 Cr ₹318.69 Cr ₹266.12 Cr ₹236.82 Cr ₹219.79 Cr ₹212.34 Cr ₹237.81 Cr ₹232.39 Cr
Cost of Materials Consumed ₹148.9 Cr ₹178.34 Cr ₹173.16 Cr ₹146.07 Cr ₹132.72 Cr ₹127.13 Cr ₹130.73 Cr ₹95.97 Cr
Purchases of Stock-in-Trade ₹1 Cr ₹1.13 Cr ₹41 Lakh ₹1.16 Cr ₹1.66 Cr ₹5.02 Cr ₹19.77 Cr ₹45.37 Cr
Changes in Inventories ₹2.05 Cr ₹10.14 Cr -₹15.18 Cr -₹9.75 Cr ₹1.68 Cr ₹1.88 Cr -₹3.27 Cr -₹19.13 Lakh
Employee Benefit Expense ₹25.13 Cr ₹21.38 Cr ₹19.61 Cr ₹16.93 Cr ₹15.26 Cr ₹14.39 Cr ₹14.11 Cr ₹14.27 Cr
Finance Costs ₹3.44 Cr ₹4.79 Cr ₹3.19 Cr ₹2.19 Cr ₹89 Lakh ₹76 Lakh ₹86 Lakh ₹86.69 Lakh
Depreciation & Amortisation ₹8.36 Cr ₹7.05 Cr ₹6.4 Cr ₹5.85 Cr ₹6.66 Cr ₹6.03 Cr ₹5.88 Cr ₹6.13 Cr
Other Expenses ₹35.84 Cr ₹59.54 Cr ₹47.73 Cr ₹42.2 Cr ₹32.55 Cr ₹30.11 Cr ₹34.77 Cr ₹34.06 Cr
Total Expenses ₹224.72 Cr ₹282.37 Cr ₹235.32 Cr ₹204.65 Cr ₹191.42 Cr ₹185.32 Cr ₹202.85 Cr ₹196.47 Cr
Profit Before Exceptional Items & Tax ₹21.84 Cr ₹36.32 Cr ₹30.8 Cr ₹32.17 Cr ₹28.37 Cr ₹27.02 Cr ₹34.96 Cr ₹35.92 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹21.84 Cr ₹36.32 Cr ₹30.8 Cr ₹32.17 Cr ₹28.37 Cr ₹27.02 Cr ₹34.96 Cr ₹35.92 Cr
Total Tax Expense ₹5.82 Cr ₹9.36 Cr ₹8.24 Cr ₹7.83 Cr ₹7.07 Cr ₹6.81 Cr ₹8.65 Cr ₹13.35 Cr
Net Profit ₹16.02 Cr ₹26.45 Cr ₹22.59 Cr ₹24.34 Cr ₹21.3 Cr ₹20.21 Cr ₹26.31 Cr ₹22.57 Cr
Other Comprehensive Income ₹18.66 Lakh ₹6 Lakh -₹20 Lakh ₹4 Lakh -₹23 Lakh ₹16 Lakh ₹4 Lakh -₹8.8 Lakh
Total Comprehensive Income ₹16.21 Cr ₹26.51 Cr ₹22.39 Cr ₹24.38 Cr ₹21.07 Cr ₹20.37 Cr ₹26.35 Cr ₹22.49 Cr
EBITDA (computed) ₹33.64 Cr ₹48.16 Cr ₹40.39 Cr ₹40.21 Cr ₹35.92 Cr ₹33.81 Cr ₹41.7 Cr ₹42.91 Cr
Basic EPS ₹23.24 ₹40.36 ₹8.65 ₹42.40 ₹37.11 ₹35.27 ₹45.90 ₹39.40
Diluted EPS ₹23.24 ₹40.36 ₹0.00 ₹42.40 ₹37.11 ₹35.27 ₹45.90 ₹39.40
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹519.94 Cr ₹549.19 Cr ₹387.15 Cr ₹308.03 Cr ₹218 Cr ₹196.24 Cr ₹192.3 Cr ₹161.27 Cr
Non-current Assets ₹299.77 Cr ₹283.41 Cr ₹168.99 Cr ₹133.52 Cr ₹74.64 Cr ₹49.21 Cr ₹56.12 Cr ₹41.14 Cr
Current Assets ₹220.17 Cr ₹265.78 Cr ₹218.16 Cr ₹174.51 Cr ₹143.36 Cr ₹147.03 Cr ₹136.18 Cr ₹120.13 Cr
Property, Plant & Equipment ₹49.8 Cr ₹45.37 Cr ₹38.46 Cr ₹35.28 Cr ₹39.75 Cr ₹43.36 Cr ₹31.75 Cr ₹33.98 Cr
Inventories ₹54.33 Cr ₹46.85 Cr ₹54.43 Cr ₹37.84 Cr ₹20.76 Cr ₹22.43 Cr ₹27.69 Cr ₹21.1 Cr
Trade Receivables ₹120.57 Cr ₹164.72 Cr ₹139.78 Cr ₹112.4 Cr ₹73.4 Cr ₹67.83 Cr ₹81.7 Cr ₹65.65 Cr
Cash & Equivalents ₹51.99 Lakh ₹34 Lakh ₹1.43 Cr ₹6.35 Cr ₹3.33 Cr ₹1.4 Cr ₹9.69 Cr ₹10.88 Cr
Equity (Net Worth) ₹402.34 Cr ₹386.82 Cr ₹213.61 Cr ₹191.06 Cr ₹166.15 Cr ₹143.94 Cr ₹123.14 Cr ₹96.8 Cr
Equity Share Capital ₹6.89 Cr ₹6.89 Cr ₹5.82 Cr ₹5.77 Cr ₹5.77 Cr ₹5.73 Cr ₹5.73 Cr ₹5.73 Cr
Borrowings (Non-current) ₹13.64 Cr ₹2.27 Cr ₹3.66 Cr ₹6.89 Cr ₹9.75 Cr ₹8.59 Cr ₹71 Lakh ₹96.5 Lakh
Borrowings (Current) ₹6.42 Cr ₹62.48 Cr ₹79.36 Cr ₹38.82 Cr ₹5.26 Cr ₹1.19 Cr ₹0 ₹1.95 Cr
Total Debt (computed) ₹20.07 Cr ₹64.75 Cr ₹83.02 Cr ₹45.71 Cr ₹15.01 Cr ₹9.78 Cr ₹71 Lakh ₹2.92 Cr
Current Liabilities ₹101.87 Cr ₹154.63 Cr ₹167.78 Cr ₹108.35 Cr ₹40.21 Cr ₹41.1 Cr ₹65.74 Cr ₹60.05 Cr
Total Liabilities ₹117.6 Cr ₹162.37 Cr ₹173.54 Cr ₹116.97 Cr ₹51.85 Cr ₹52.3 Cr ₹69.16 Cr ₹64.47 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹44.57 Cr ₹47.67 Cr -₹22.91 Cr -₹11.56 Cr -₹22.15 Cr
Investing Cash Flow ₹4.14 Cr ₹89.7 Cr -₹16.1 Cr -₹13.95 Cr ₹21.76 Cr
Financing Cash Flow -₹48.8 Cr ₹69.25 Cr ₹34.17 Cr ₹28.52 Cr ₹2.32 Cr
Capital Expenditure ₹14.52 Cr -₹20.3 Cr ₹10.36 Cr ₹5.06 Cr ₹4.76 Cr
Free Cash Flow (computed) ₹30.04 Cr ₹27.37 Cr -₹33.27 Cr -₹16.62 Cr -₹26.91 Cr
Dividends Paid ₹68.92 Lakh ₹58 Lakh ₹39.47 Lakh ₹0 ₹0
Net Change in Cash -₹9.62 Lakh ₹205.41 Cr -₹4.83 Cr ₹3 Cr ₹1.93 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹56.54 Cr ₹41.41 Cr ₹41.7 Cr ₹94.37 Cr ₹80.28 Cr ₹67.34 Cr ₹64.45 Cr ₹92.06 Cr
Other Income ₹4.44 Cr ₹2.28 Cr ₹4.21 Cr ₹1.62 Cr ₹2.26 Cr ₹3.79 Cr ₹4.6 Cr ₹3.9 Cr
Total Income ₹60.98 Cr ₹43.69 Cr ₹45.91 Cr ₹95.99 Cr ₹82.54 Cr ₹71.13 Cr ₹69.05 Cr ₹95.96 Cr
Cost of Materials Consumed ₹41.97 Cr ₹20.82 Cr ₹31.28 Cr ₹54.83 Cr ₹51.35 Cr ₹45.25 Cr ₹26.93 Cr ₹54.8 Cr
Purchases of Stock-in-Trade ₹68.88 Lakh ₹31.26 Lakh ₹0 ₹0 ₹0 ₹49 Lakh ₹0 ₹64 Lakh
Changes in Inventories -₹1.98 Cr ₹3.99 Cr -₹7.97 Cr ₹8 Cr ₹3.54 Cr -₹7.56 Cr ₹14.76 Cr -₹59 Lakh
Employee Benefit Expense ₹6.14 Cr ₹6.52 Cr ₹6.51 Cr ₹5.96 Cr ₹5.67 Cr ₹5.29 Cr ₹5.42 Cr ₹4.99 Cr
Finance Costs ₹51.47 Lakh ₹54.8 Lakh ₹96 Lakh ₹1.42 Cr ₹1.48 Cr ₹1.41 Cr ₹88 Lakh ₹1.02 Cr
Depreciation & Amortisation ₹2.04 Cr ₹2.1 Cr ₹2.17 Cr ₹2.06 Cr ₹1.82 Cr ₹1.86 Cr ₹1.75 Cr ₹1.61 Cr
Other Expenses ₹9.67 Cr ₹6.3 Cr ₹9.54 Cr ₹10.32 Cr ₹15.12 Cr ₹15.52 Cr ₹11.68 Cr ₹17.23 Cr
Total Expenses ₹59.06 Cr ₹40.59 Cr ₹42.49 Cr ₹82.59 Cr ₹78.98 Cr ₹62.26 Cr ₹61.42 Cr ₹79.7 Cr
Profit Before Exceptional Items & Tax ₹1.93 Cr ₹3.1 Cr ₹3.42 Cr ₹13.4 Cr ₹3.56 Cr ₹8.87 Cr ₹7.63 Cr ₹16.26 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹1.93 Cr ₹3.1 Cr ₹3.42 Cr ₹13.4 Cr ₹3.56 Cr ₹8.87 Cr ₹7.63 Cr ₹16.26 Cr
Total Tax Expense ₹54.91 Lakh ₹1.18 Cr ₹69 Lakh ₹3.4 Cr ₹1.1 Cr ₹2.37 Cr ₹2.14 Cr ₹4.08 Cr
Net Profit ₹1.38 Cr ₹1.92 Cr ₹2.73 Cr ₹10 Cr ₹2.28 Cr ₹6.5 Cr ₹5.49 Cr ₹12.18 Cr
Other Comprehensive Income ₹6.18 Lakh ₹9.47 Lakh ₹6.49 Lakh -₹3 Lakh ₹21 Lakh -₹5 Lakh -₹5 Lakh -₹5 Lakh
Total Comprehensive Income ₹1.44 Cr ₹2.01 Cr ₹2.79 Cr ₹9.97 Cr ₹2.49 Cr ₹6.45 Cr ₹5.44 Cr ₹12.13 Cr
EBITDA (computed) ₹4.48 Cr ₹5.75 Cr ₹6.55 Cr ₹16.88 Cr ₹6.86 Cr ₹12.14 Cr ₹10.26 Cr ₹18.89 Cr
Basic EPS ₹2.00 ₹2.78 ₹3.96 ₹14.51 ₹3.48 ₹8.30 ₹7.90 ₹20.26
Diluted EPS ₹2.00 ₹2.78 ₹3.96 ₹14.51 ₹3.48 ₹8.30 ₹7.90 ₹0.00
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Bharat Parenterals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Bharat Parenterals Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 67.17%, foreign institutional investors hold 0.11%, domestic institutional investors hold 1.06%, retail and other public shareholders hold 31.66% of Bharat Parenterals Limited. The company had 3,095 shareholders on record.

Promoters: 67.17%DII (Domestic Institutional): 1.06%FII (Foreign Institutional): 0.11%Retail & Others: 31.66%
Mar 2026
QUARTER
67.17% Promoters
1.06% DII (Domestic Institutional)
0.11% FII (Foreign Institutional)
31.66% Retail & Others
Promoter holding - history
Now 67.17% · Mar 2026High 73.84% · Jun 2023Low 65.35% · Sep 2024
64%66.8%69.5%72.3%75%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 73.84%Sep 2023: 73.84%Dec 2023: 73.84%Mar 2024: 73.27%Jun 2024: 73.27%Sep 2024: 65.35%Dec 2024: 67.20%Mar 2025: 67.20%Jun 2025: 67.19%Sep 2025: 67.19%Dec 2025: 67.19%Mar 2026: 67.17%73.84%65.35%67.17%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters67.17%67.19%67.19%67.19%67.20%67.20%
Public32.83%32.81%32.81%32.81%32.80%32.80%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters67.17%67.20%73.27%
Public32.83%32.80%26.73%
Promoter change (YoY, %pts)-0.03-6.07-

Group Structure of Bharat Parenterals Limited

Bharat Parenterals Limited has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Bharat Parenterals Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
1
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Innoxel Lifesciences Private Limited U24290GJ2020PTC117407 -
Varenyam Biolifesciences Private Limited U24290GJ2022PTC133332 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Bharat Parenterals Limited

Open charges
₹145.09 Cr
Satisfied charges
₹34.12 Cr
Breakdown by lending institutions
Axis Bank Limited₹129.59 Cr
Sidbi₹12.00 Cr
Hdfc Bank Limited₹2.04 Cr
Others₹1.39 Cr
Axis Bank Ltd₹0.08 Cr
Latest charge details
DateLenderAmountStatus
16 Feb 2026 Others ₹1.39 Cr Open
17 Dec 2025 Sidbi ₹12 Cr Open
26 Nov 2025 Hdfc Bank Limited ₹12.86 Lakh Open
16 Dec 2024 Hdfc Bank Limited ₹21.5 Lakh Open
21 Sep 2024 Hdfc Bank Limited ₹78 Lakh Open

Total charge records: 40 View all charges

Employees and EPFO Compliance at Bharat Parenterals Limited

Bharat Parenterals Limited has a workforce of 396 employees as of Dec 08, 2025.

Employee count
396
Active EPFO establishments
1
Employee growth
3.66%
Premium access

Employee and EPFO history for Bharat Parenterals Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Bharat Parenterals Limited

Premium access

GST registrations and filing compliance for Bharat Parenterals Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Bharat Parenterals Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Bharat Parenterals Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Bharat Parenterals Limited

Premium access

MSME payment history for Bharat Parenterals Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Bharat Parenterals Limited

Premium access

Corporate group structure for Bharat Parenterals Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Bharat Parenterals Limited

Premium access

MCA filings and documents for Bharat Parenterals Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Bharat Parenterals Limited

Charges
16 Feb 2026
A charge with Others amounted to Rs. 1.39 Cr with Charge ID 101250276 was registered on 16 Feb 2026.
Charges
17 Dec 2025
A charge with Sidbi amounted to Rs. 12.00 Cr with Charge ID 101209961 was registered on 17 Dec 2025.
Charges
26 Nov 2025
A charge with Hdfc Bank Limited amounted to Rs. 0.13 Cr with Charge ID 101189310 was registered on 26 Nov 2025.
Activity
26 Sep 2025
Bharat Parenterals Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Charges
13 Aug 2025
A charge with Axis Bank Limited of Rs. 84.36 Cr registered on 04 Feb 2008 with Charge ID 10120617 was modified on 13 Aug 2025.
Directors
28 Jul 2025
Alkesh Jayantilal Shah was appointed as a Director on 28 Jul 2025 & has been associated with this company since 1 year 24 days.

Frequently Asked Questions about Bharat Parenterals Limited

Bharat Parenterals Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 03 September 1992 (34+ years old) and is registered under CIN L24231GJ1992PLC018237. Listed on BSE: 541096. The company has 396 employees.

Bharat Parenterals Limited reported revenue of ₹345.43 Cr for FY 2026 (up 1.48% YoY) based on consolidated BSE filings.

The current directors of Bharat Parenterals Limited are:

The primary industry of Bharat Parenterals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Bharat Parenterals Limited is listed on BSE with code 541096.

Bharat Parenterals Limited can be reached at the registered office: Survey No. 144A Jarod – Samlaya Road Haripura Savli, Vadodara, Gujarat, India – 391520, or through the website bplindia.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available